Judge Advanced Claims Against ExThera Medical Corporation
A federal judge allowed new negligence and wrongful death claims to proceed against the company.
Updated on Oct. 9, 2026 in Cancer
A federal judge in San Francisco signaled she will allow additional claims against ExThera Medical Corporation in a lawsuit regarding its ONCObind cancer treatment. Patients alleged the company marketed the $45,000 treatment as a cure for metastatic cancer despite reports of severe health decline.
Why it matters
The legal development addresses allegations that the company's treatment caused patient deaths and physical harm. The judge determined the plaintiffs successfully amended their complaint to provide necessary evidence of negligence and wrongful death.
The court reviewed a first amended complaint containing statements from doctors alleging that ExThera's actions contributed to patient deaths. Evidence includes promotional materials and website claims previously attributed to a former board member.
The players
ExThera Medical Corporation
A medical entity headquartered in the Bay Area that marketed the ONCObind treatment for metastatic cancer.
The details
Plaintiffs alleged that many individuals experienced increased cancer markers and deteriorating health following the ONCObind treatment. ExThera operated the service in Antigua for $45,000 per round. The court previously dismissed claims of civil RICO, battery, and negligence, but the updated complaint now allows the negligence and wrongful death claims to move forward.
Timeline
March 2025: Plaintiffs filed the lawsuit against ExThera.
May 2026: The judge dismissed several initial claims.
October 9, 2026: The judge indicated her intent to advance additional claims.
Health Landscape
This case sits within the framework of the Federal Rules of Civil Procedure regarding the sufficiency of evidence required to advance civil claims. The ruling marks a shift in the court's stance on the viability of negligence and wrongful death allegations against the medical company.
Readers managing cancer should exercise extreme caution with any treatment offered outside of clinical settings or standard medical oversight. Always verify the clinical trial status of any experimental therapy and discuss unconventional treatment claims with your oncologist.
The takeaway
The court's decision highlights the importance of vetting any medical claims that deviate from standard oncology protocols. Patients and their families should remain skeptical of treatments that promise cures for metastatic cancer outside of peer-reviewed clinical research programs.
Further reading
For more on the evaluation of new treatments, visit our Cancer section.
Source note: This article includes information reported by Court House News Service.
